Overexpression of Syk tyrosine kinase in peripheral T-cell lymphomas

被引：107

作者：

Feldman, A. L. ^{[1
]}

Sun, D. X. ^{[1
]}

Law, M. E. ^{[1
]}

Novak, A. J. ^{[2
]}

Attygalle, A. D. ^{[3
]}

Thorland, E. C. ^{[1
]}

Fink, S. R. ^{[1
]}

Vrana, J. A. ^{[1
]}

Caron, B. L. ^{[1
]}

Morice, W. G. ^{[1
]}

Remstein, E. D. ^{[1
]}

Grogg, K. L. ^{[1
]}

Kurtin, P. J. ^{[1
]}

Macon, W. R. ^{[1
]}

Dogan, A. ^{[1
]}

机构：

[1] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN 55905 USA

[2] Mayo Clin, Dept Hematol, Rochester, MN 55905 USA

[3] Royal Marsden Hosp, Dept Histopathol, London SW3 6JJ, England

来源：

LEUKEMIA | 2008年 / 22卷 / 06期

关键词：

peripheral T-cell lymphoma; Syk; tyrosine kinase; phosphorylation;

D O I：

10.1038/leu.2008.77

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Peripheral T-cell lymphomas (PTCLs) are fatal in the majority of patients and novel treatments, such as protein tyrosine kinase (PTK) inhibition, are needed. The recent finding of SYK/ITK translocations in rare PTCLs led us to examine the expression of Syk PTK in 141 PTCLs. Syk was positive by immunohistochemistry (IHC) in 133 PTCLs (94%), whereas normal T cells were negative. Western blot on frozen tissue (n = 6) and flow cytometry on cell suspensions (n = 4) correlated with IHC results in paraffin. Additionally, western blot demonstrated that Syk-positive PTCLs show tyrosine (525/526) phosphorylation, known to be required for Syk activation. Fluorescence in situ hybridization showed no SYK/ITK translocation in 86 cases. Overexpression of Syk, phosphorylation of its Y525/526 residues and the availability of orally available Syk inhibitors suggest that Syk merits further evaluation as a candidate target for pharmacologic PTK inhibition in patients with PTCL.

引用

页码：1139 / 1143

页数：5

共 25 条

[1] Functional role for Syk tyrosine kinase in natural killer cell-mediated natural cytotoxicity
Brumbaugh, KM
Binstadt, BA
Billadeau, DD
Schoon, RA
Dick, CJ
Ten, RM
Leibson, PJ
[J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1997, 186 (12) : 1965 - 1974
[2] Differential regulation by leukotrienes and calcium of Fcγ receptor-induced phagocytosis and Syk activation in dendritic cells versus macrophages
Canetti, Claudio
Aronoff, David M.
Choe, Mun
Flamand, Nicolas
Wettlaufer, Scott
Toews, Galen B.
Chen, Gwo-Hsiao
Peters-Golden, Marc
[J]. JOURNAL OF LEUKOCYTE BIOLOGY, 2006, 79 (06) : 1234 - 1241
[3] CHAN AC, 1994, J IMMUNOL, V152, P4758
[4] SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma
Chen, Linfeng
Monti, Stefano
Juszczynski, Przemyslaw
Daley, John
Chen, Wen
Witzig, Thomas E.
Habermann, Thomas M.
Kutok, Jeffery L.
Shipp, Margaret A.
[J]. BLOOD, 2008, 111 (04) : 2230 - 2237
[5] Peripheral T-cell lymphoma with follicular involvement and a CD4+/bcl-6+phenotype
de Leval, L
Savilo, E
Longtine, J
Ferry, JA
Harris, NL
[J]. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2001, 25 (03) : 395 - 400
[6] Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma -: The MD Anderson Cancer Center experience
Escalón, MP
Liu, NS
Yang, Y
Hess, M
Smith, TL
Dang, NH
[J]. CANCER, 2005, 103 (10) : 2091 - 2098
[7] Spleen tyrosine kinase (Syk), a novel target of curcumin, is required for B lymphoma growth
Gururajan, Murali
Dasu, Trivikram
Shahidain, Seif
Jennings, C. Darrell
Robertson, Darrell A.
Rangnekar, Vivek M.
Bondada, Subbarao
[J]. JOURNAL OF IMMUNOLOGY, 2007, 178 (01) : 111 - 121
[8] Altered B-cell receptor signaling kinetics distinguish human follicular lymphoma. B cells from tumor-infiltrating nonmalignant B cells
Irish, Jonathan M.
Czerwinski, Debra K.
Nolan, Garry P.
Levy, Ronald
[J]. BLOOD, 2006, 108 (09) : 3135 - 3142
[9] Jaffe ES, 2001, Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues, P189
[10] Syk-dependent mTOR activation in follicular lymphoma cells
Leseux, Ludivine
Hamdi, Safouane M.
al Saati, Talal
Capilla, Florence
Recher, Christian
Laurent, Guy
Bezombes, Christine
[J]. BLOOD, 2006, 108 (13) : 4156 - 4162

← 1 2 3 →